Skip to main content

What we do

research

What we do

QPHI will serve as a platform and driver of health research through recruiting large numbers of the Qatari population to contribute biological samples and information about their health and lifestyle.

Qatar Biobank population-based cohort study

Qatar Biobank cohort study is a population-based long-term study aiming to collect high-quality biological samples and annotated data for 60,000 participants from Qataris and long-term Qatar residents who live in Qatar for at least 15 years (age ≥ 18 years) to promote medical research in Qatar and worldwide. 

COVID-19 Biorepository

The COVID-19 Biorepository is a National Disease-based study aiming to collect adequate health information and biological samples of 6,000 participants to enable evidence-based research towards the discovery and development of novel healthcare interventions and to facilitate research projects related to the COVID-19 pandemic.

Qatar Birth Cohort Study

The Qatari Birth Cohort study is the first mother-child cohort study in the Gulf that aims to assess the synergetic role of environmental exposure and genetic factors in the development of chronic diseases. The aim is to follow up 3,000 women during their pregnancy, at delivery and then follow up their children and father (triads: Mother-Child-Father) for a period of 5 years.

research
Latest from Press
Read more News
Read
 Qatar to become first state in middle east to have iOT enabled Health care system

Qatar to become first state in middle east to have iOT enabled Health care system

Read
 Qatar to become first state in middle east to have iOT enabled Health care system - international

Qatar to become first state in middle east to have iOT enabled Health care system - international

Read
 How QF is carving the path toward Qatar’s healthier future  - Business

How QF is carving the path toward Qatar’s healthier future - Business

Read
 I aspire that one day medicine attains the level of precision seen in engineering,” says QF expert - business

I aspire that one day medicine attains the level of precision seen in engineering,” says QF expert - business

Our Partners
partners
partners
partners
partners